Home › Research › Tau biomarkers
[New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]
Vogelgsang J, Wiltfang J.. Der Nervenarzt, 2019-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In accordance with the current German dementia guidelines, the dementia biomarkers amyloid beta 42, the tau peptides total tau and phosphorylated tau 181 are recommended for cerebrospinal fluid (CSF)-based diagnostics of dementia. Several studies have clearly shown that determination of the amyloid beta 42 to amyloid beta 40 peptide ratio is superior to the interpretation of amyloid beta 42 alone and should be implemented in the clinical work-up; however, in recent years different studies have presented many other innovative CSF and blood-based biomarkers. Besides CSF-based neurochemical diagnostics of dementia promising novel protocols for the detection of amyloid beta peptides in blood have meanwhile been published, which can currently be used in clinical studies for blood-based early diagnostics of Alzheimer's dementia.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that the amyloid beta 42 to amyloid beta 40 ratio is superior to amyloid beta 42 alone for cerebrospinal fluid diagnosis, and that blood-based amyloid beta detection methods are currently usable in clinical studies for early diagnosis. It concerns diagnosis and does not report any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vogelgsang, J., & Wiltfang, J. (2019). [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]. Der Nervenarzt. https://doi.org/10.1007/s00115-019-0772-9
Vancouver
Vogelgsang J, Wiltfang J. [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]. Der Nervenarzt. 2019. doi:10.1007/s00115-019-0772-9. PMID: 31407045.
BibTeX
@article{vogelgsang2019-31407045,
author = {Vogelgsang, J. and Wiltfang, J.},
title = {{[New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]}},
journal = {Der Nervenarzt},
year = {2019},
doi = {10.1007/s00115-019-0772-9},
pmid = {31407045},
url = {https://doi.org/10.1007/s00115-019-0772-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Several studies have clearly shown that determination of the amyloid beta 42 to amyloid beta 40 peptide ratio is superior to the interpretation of amyloid beta 42 alone and should be implemented in the clinical work-up; however, in recent years different studies have presented many other innovative CSF and blood-based biomarkers.
- Besides CSF-based neurochemical diagnostics of dementia promising novel protocols for the detection of amyloid beta peptides in blood have meanwhile been published, which can currently be used in clinical studies for blood-based early diagnostics of Alzheimer's dementia.
- Following further validation and assay optimization these blood assays should be available for routine diagnostics in the near future.
Why it matters
This review notes that the amyloid beta 42 to amyloid beta 40 ratio is superior to amyloid beta 42 alone for cerebrospinal fluid diagnosis, and that blood-based amyloid beta detection methods are currently usable in clinical studies for early diagnosis. It concerns diagnosis and does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Der Nervenarzt) |
| Journal's citation record | 0 / 4 | Der Nervenarzt: journal h-index 61 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.6 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 1 / 6 | Cited 0.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jens Wiltfang: h-index 95 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Göttingen: institution h-index 934 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31407045) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.